Tumor necrosis factor-mediated interferon signaling pathway proteins

The TNF-mediated interferon signaling pathway proteins encompass a network of signaling molecules that facilitate the crosstalk between Tumor Necrosis Factor (TNF) and Type I Interferon (IFN) systems. In this pathway, TNF stimulation (primarily through TNFR1) induces the expression of IFN-beta via transcription factors such as IRF1 (Yarilina et al., 2008). The resulting IFN-beta then signals through the IFNAR1/IFNAR2 receptor complex in an autocrine or paracrine manner, activating the JAK-STAT signaling cascade involving JAK1, TYK2, STAT1, and STAT2 (NIH, 2021). This synergy leads to the robust induction of interferon-stimulated genes (ISGs), creating a sustained inflammatory environment characteristic of chronic autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. Therapeutic strategies targeting this pathway include TNF-alpha antagonists, which block the initial trigger, and JAK inhibitors or IFNAR blockers, which disrupt the downstream amplification loop. Monitoring the 'interferon signature' or ISG expression serves as a key biomarker for pathway activity and treatment response. Understanding this crosstalk is essential for managing patients who may be refractory to single-cytokine blockade.

Other names

TNF-IFN crosstalkTNF-induced interferon signatureTNF-IFN-beta autocrine loopTNF-mediated ISG inductionTNF-IFN-gamma synergistic signaling

Inhibition of TNF-alpha signaling, blockade of type I interferon receptors, or inhibition of downstream JAK-STAT signaling kinases to disrupt the synergistic inflammatory loop.